Ipsen SA

Ipsen has completed its acquisition of Memo Therapeutics AG, a late-stage biotech company focused on the first-in-class monoclonal antibody potravitug. Potravitug targets BK polyomavirus reactivation in kidney transplant recipients, a condition with no approved targeted therapies that affects approximately 30% of patients within the first year after transplant. The acquisition adds potravitug to Ipsen's Rare Disease pipeline, building on promising Phase II results from the SAFE KIDNEY II trial, the largest placebo-controlled study in this patient population. Over 100,000 kidney transplants are performed each year worldwide, with more than 28,000 in the U.S. and over 90,000 patients on the waiting list.

Ipsen repurchased a total of 24,258 of its own shares between July 13 and July 17, 2026, at a daily volume-weighted average price of 159.0596 euros, according to a regulatory filing. The daily breakdown shows 5,500 shares bought on July 13 at 161.6092 euros, 5,000 shares on July 14 at 158.4579 euros, 5,000 shares on July 15 at 159.6458 euros, 4,390 shares on July 16 at 157.0540 euros, and 4,368 shares on July 17 at 157.8826 euros. All transactions were executed on the Euronext Paris market under the company's ongoing buy-back programme.

The global carcinoid syndrome market is expected to record significant growth during the 2025–2035 forecast period, supported by the rising prevalence of neuroendocrine tumors, improved diagnostic capabilities and increasing demand for effective symptom management. Market expansion is also being supported by advances in targeted treatments and the availability of U.S. Food and Drug Administration-approved therapies, with somatostatin analogs, telotristat ethyl and peptide receptor radionuclide therapy remaining important components of treatment strategies. North America holds the largest share of the market, benefiting from advanced healthcare infrastructure, established neuroendocrine tumor treatment networks and broad access to approved medicines. Key drivers include the rising prevalence of neuroendocrine tumors, advancements in treatment options, greater awareness and earlier diagnosis, and increasing research investment, while high treatment costs and limited options for advanced cases remain major challenges. Prominent companies operating in the market include Novartis AG, Ipsen, Lexicon Pharmaceuticals and Crinetics Pharmaceuticals.

Ipsen reported positive topline results from the Phase 3 BEOND study for Dysport, showing a significant reduction in monthly migraine days for both episodic and chronic migraine patients compared to placebo. The study included two cohorts, E-BEOND for episodic migraines and C-BEOND for chronic migraines, both of which met their primary endpoints. Dysport was well-tolerated with a consistent safety profile, and Ipsen noted it is the only botulinum-derived drug to demonstrate statistically significant efficacy in episodic migraines. The drug, an injectable botulinum neurotoxin type A, has been approved in over 90 countries since 2009.

Ipsen repurchased 11,795 of its own shares between June 22 and June 26, 2026, at a weighted average price of 161.1856 euros per share. The daily volumes were 2,139 shares on June 22 at 155.6891 euros, 2,500 shares on June 24 at 163.2722 euros, 3,000 shares on June 25 at 162.7671 euros, and 4,156 shares on June 26 at 161.6177 euros. All transactions were executed on the XPAR market under the company's buy-back programme.

Ipsen agreed to acquire Swiss biotech Memo Therapeutics for an upfront payment of 200 million euros, with additional milestone-based payments that could bring the total above 700 million euros, or roughly 800 million dollars. The deal centers on potravitug, a Phase II monoclonal antibody targeting BK polyomavirus-associated nephropathy in kidney transplant patients, a condition with no approved targeted therapies. At closing, expected before the end of the third quarter, Ipsen will pay 200 million euros on a cash-and-debt-free basis, with the remainder tied to development, regulatory, and commercial milestones. Potravitug holds FDA fast-track and EU orphan drug designations, and Phase II trial results showed 24.4% of treated patients achieved undetectable viral levels by week 38 versus 13.0% for placebo, with no treatment-related serious adverse events. Ipsen plans to start a pivotal Phase II/III study later this year, while Memo Therapeutics' other assets will be spun into a new entity called Memorises Bio owned by existing shareholders. This is Ipsen's second acquisition this week, following its deal to acquire Kartos Therapeutics for up to 1.3 billion dollars in milestone payments.

Ipsen has agreed to acquire Kartos Therapeutics, a clinical-stage biopharmaceutical company, for $450 million upfront and up to $1.3 billion in milestone payments, bringing the total potential deal value to $1.75 billion. The acquisition centers on navtemadlin, an oral MDM2 inhibitor in a Phase III trial for myelofibrosis, with top-line data expected in 2027. Ipsen CEO David Loew said the deal strengthens the company's late-stage oncology pipeline and that navtemadlin could become a new treatment option as early as 2028. The transaction is expected to close by the end of the third quarter, subject to antitrust clearance, and is projected to add to Ipsen's core operating income starting in 2029.

European stocks were subdued on Monday, with the pan-European Stoxx 600 marginally lower at 635.36, while technology shares rallied after South Korea announced a $576 billion semiconductor and AI investment plan backed by Samsung and SK Hynix. The German DAX was marginally higher, France's CAC 40 dropped 0.4 percent, and the U.K.'s FTSE 100 slipped 0.2 percent as crude oil prices rose slightly on renewed U.S.-Iran tensions. Technology stocks gained, with ASML Holding, Infineon, and STMicroelectronics climbing 1 to 3 percent. Nordex Group shares rose about 1 percent after securing a 325-MW order in the United States, while Prosus N.V. rallied 2.4 percent after reporting an 84 percent jump in full-year adjusted core profit. French biotech Ipsen advanced 1.7 percent after agreeing to acquire U.S. biotech Kartos Therapeutics in a deal worth up to $1.75 billion, and BT Group rose about 1 percent after signing an agreement to combine its international business in a joint venture with Verizon.